Pharma News

A new study suggests that women with deficiencies of luteinizing hormone (LH) and low dose human chorionic gonadotropin (hCG) can improve the outcome of in vitro fertilization (IVF).

AstraZeneca announced top-line results from SATURN. SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80 mg on the progression of atherosclerosis in high risk patients.

A New studies suggested a new hormonal therapy to reduce risk of venous thromboembolism than oral estrogen-only hormone therapy agents (contraceptive pills). In this study they compared Estradiol transdermal system with oral estrogen hormone therapy.

Aventis Pharma Limited (part of the Sanofi Group) announced on 24^th August, 2011 that it has entered into a definitive agreement to acquire Universal Medicare Private Limited’s business of marketing and distribution of branded nutraceutical formulations in India. Also, approximately 750 commercial employees will transition to Aventis Pharma Ltd. The transaction has been approved by the Boards of Directors of both companies.

Eli Lilly India (Lilly) and Lupin Limited (Lupin) announced on 29^th July, 2011 that they have entered into a strategic collaboration to promote and distribute Lilly’s Huminsulin range of products, including Huminsulin RTM, Huminsulin NPHTM, Huminsulin 50/50TM, Huminsulin 30/70TM and Humapen Ergo II. Lupin’s India formulations business will promote and distribute the range of products in India and Nepal, virtually doubling the number of sales representatives behind the diabetes care product.

Lupin Pharmaceuticals, Inc. (LPI) announced on 29^th aug, 2011 that it has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Extended-Release Tablets, 100, 200 and 300 mg strengths. Lupin will begin shipping its Tramadol ER shortly.

The Institute of Pharmacy has been established with a view to promote excellence in pharmaceutical education and to prepare young men and women to meet the challenges in the area of pharmaceutical industries, education, research and development and marketing. We aim to provide degree, postgraduate, doctoral and postdoctoral level education at this centre of excellence. The pharmacy profession in Gujarat and western part of India has been striving for such a centre and establishment of IP.

The US health regulator has imposed an import ban on products made at Dr Reddy's Laboratories' Mexican plant for violation of current good manufacturing practices (CGMP).

The FDA has sent a warning letter to Cadila Healthcare’s Ahmedabad, India finished products plant after an inspection found GMP deviations.